NASDAQ:RDNT - RadNet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.30 -0.05 (-0.35 %)
(As of 06/25/2018 06:00 AM ET)
Previous Close$14.30
Today's Range$14.10 - $14.45
52-Week Range$7.40 - $14.85
Volume582,667 shs
Average Volume234,277 shs
Market Capitalization$692.24 million
P/E Ratio49.31
Dividend YieldN/A
Beta0.42
RadNet logoRadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Debt-to-Equity Ratio4.90
Current Ratio1.12
Quick Ratio1.12

Price-To-Earnings

Trailing P/E Ratio49.31
Forward P/E Ratio38.65
P/E Growth4.91

Sales & Book Value

Annual Sales$922.19 million
Price / Sales0.75
Cash Flow$1.7546 per share
Price / Cash8.15
Book Value$1.47 per share
Price / Book9.73

Profitability

EPS (Most Recent Fiscal Year)$0.29
Net Income$50,000.00
Net Margins-0.66%
Return on Equity18.77%
Return on Assets1.74%

Miscellaneous

Employees7,440
Outstanding Shares48,240,000

The Truth About Cryptocurrencies

RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) posted its quarterly earnings data on Wednesday, May, 9th. The medical research company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.04 by $0.19. The medical research company had revenue of $231.39 million for the quarter, compared to analyst estimates of $234.32 million. RadNet had a positive return on equity of 18.77% and a negative net margin of 0.66%. The company's quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) earnings per share. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for RadNet.

What price target have analysts set for RDNT?

3 brokers have issued 12-month price targets for RadNet's stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate RadNet's stock price to reach $14.6667 in the next twelve months. View Analyst Ratings for RadNet.

Who are some of RadNet's key competitors?

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Dr. Howard G. Berger M.D., Chairman, Pres, CEO & Treasurer (Age 72)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 47)
  • Mr. Jeffrey L. Linden, Exec. VP & Gen. Counsel (Age 75)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 62)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 57)

Has RadNet been receiving favorable news coverage?

News coverage about RDNT stock has trended somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RadNet earned a news sentiment score of 0.16 on Accern's scale. They also gave news coverage about the medical research company an impact score of 45.40 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are RadNet's major shareholders?

RadNet's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.51%), Dimensional Fund Advisors LP (3.21%), JPMorgan Chase & Co. (1.07%), Northern Trust Corp (0.86%), Millennium Management LLC (0.61%) and Allianz Asset Management GmbH (0.58%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Thrivent Financial for Lutherans, State Board of Administration of Florida Retirement System, Dynamic Technology Lab Private Ltd, Highbridge Capital Management LLC, Northern Trust Corp, Wedge Capital Management L L P NC and Piermont Capital Management Inc.. Company insiders that have sold RadNet company stock in the last year include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, ClariVest Asset Management LLC, EAM Global Investors LLC, Guggenheim Capital LLC, Financial Gravity Wealth Inc., Matarin Capital Management LLC and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $14.30.

How big of a company is RadNet?

RadNet has a market capitalization of $692.24 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,440 workers across the globe.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVENUE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (RDNT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.